Recent Advances in the Usage of Mitomycin (Oncology)
Read Online
Share

Recent Advances in the Usage of Mitomycin (Oncology) by I. C. Henderson

  • 462 Want to read
  • ·
  • 55 Currently reading

Published by S. Karger AG (Switzerland) .
Written in English

Subjects:

  • Chemotherapy,
  • Medical / Nursing

Book details:

The Physical Object
FormatPaperback
Number of Pages84
ID Numbers
Open LibraryOL12930314M
ISBN 103805557752
ISBN 109783805557757

Download Recent Advances in the Usage of Mitomycin (Oncology)

PDF EPUB FB2 MOBI RTF

Mitomycin C is used as an antineoplastic agent and for slowing of fibroblast formation in open-angle glaucoma. Recently, mitomycin C has been used to induce tumor responses in patients with many types of cancer. For example, mitomycin C has been used in combination with other drugs for adenocarcinoma of the stomach and pancreas as well as palliative treatment of anal, bladder, breast, . A prospective randomized study to compare the effectiveness of pleurodesis by two new sclerosing agents: OK‐ and mitomycin C were conducted in S3 Cited by: The use of mitomycin C at the time of surgery 4 and the larger ablation diameter and small beam flying spot of modern lasers 5 both help to decrease the risk of haze formation. This combination has increased my comfort in using a shorter steroid course. The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell count, differential, and hemoglobin.

  The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell count, differential, and hemoglobin. During glaucoma surgery, a drug called mitomycin-c may be applied to the eye to prevent scarring and improve the success rates of glaucoma surgery. Mitosol is a new solution of mitomycin-c ophthalmic that is applied by saturated sponges to the site for 2 minutes. It may be more straightforward to store and use than the current. Other studies have found treatment with mitomycin C reduces the risk of recurrence by percent. Dr. Ristau notes that intravesical gemcitabine has fewer side effects compared with mitomycin C. Side effects for both types of chemotherapy are usually minor and may include an increase in the need to urinate, and the urge to urinate more often.   Recent advances reported for antibody-based biosensors for environmental applications have primarily been focused toward these limitations. For example, the simultaneous detection of six hazardous bacteria and protein toxins was demonstrated on a planar waveguide array biosensor [27].

  Mitomycin ophthalmic is a liquid medicine that is applied first to a tray of tiny sponges. The sponges will soak in the mitomycin for at least 60 minutes. Once the sponges are saturated with mitomycin, your surgeon will place the sponges directly onto your eye. The sponges will be left in place for 2 minutes and then removed. Abstract. Despite recent advances in diagnostic methods, many patients with gastric cancer are seen with stage II or more advanced disease. Although there has been some improvement in survival rates due to meticulous attention to anatomic dissection with systematic lymphatic removal [1], the persistently dismal survival rates for patients with advanced disease seem to indicate that extensive.   Our typical usage protocol is 12 seconds of application of % mitomycin-C, then rinsing of the area with at least 30 cc of BSS. Another very good question that has arisen lately is about the use of mitomycin-C in patients with high astigmatism who may not be undergoing a deep ablation. In this study, we designed, formulated, and investigated the potential antitumor activity of a folate receptor (FR)-mediated double-targeted drug delivery system. The system comprised of the FR ligand folic acid (FA), glycine-phenylalanine-leucine-glycine (Gly-Phe-Leu-Gly, GFLG), which can be specifically cleaved by cathepsin B, and the anticancer drug mitomycin C (MMC). The antitumor effect.